Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...

SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug ...

Bausch + Lomb CEO Brent Saunders joins 'Squawk on the Street' to discuss the impacts of artificial intelligence on healthcare ...

By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time ...

The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other ...

When we treat cancer patients, their disease can overcome treatment through its innate capacity to adapt. This is at the ...

In the search for new drugs, artificial intelligence in the form of diffusion models is being used in drug design. What ...

For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the ...

The FDA is testing real-time clinical trial reporting in an effort to speed up the drug review and approval process.

In part 2 of a multi-part series, David Schoneker, president, Black Diamond Regulatory Consulting, explains what drives the ...